Figure 3.

Analysis comparing gemtuzumab ozogamicin versus standard treatment in the three subgroups defined by the genotypes with regard to clinical endpoints. Effect estimates are taken from multivariate Cox models and are therefore adjusted for age, gender, European LeukemiaNet 2010 risk class and white blood cell count. HR: hazard ratio; 95% CI: 95% confidence interval; EFS: eventfree survival; RFS: relapsefree survival; CR: complete remission; CIR: cumulative incidence of relapse; CID: cumulative incidence of death in remission: GO: gemtuzumab ozogamicin.